MESO Earnings Date: Mar 4, 2027 (Estimated) — Mesoblast Limited American Depositary Shares
XNAS · Healthcare · Biotechnology
Updated
When is MESO's next earnings date?
Mesoblast Limited American Depositary Shares (MESO) is expected to report H1 2027 earnings on Thursday, March 4, 2027 at 5:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is revenue of $52.3M.
How did MESO do in its last earnings report?
In its most recent report on Aug 26, 2026 (FY 2026), Mesoblast Limited American Depositary Shares posted EPS of -$0.04 versus the -$0.11 estimate, a beat of 91.2%. Revenue was $120.3M against a $54.9M estimate. The stock's 1-day post-earnings move was +8.0%.
How much does MESO stock move after earnings?
MESO beat EPS estimates in 4 of its last 6 reported quarters. Over the last 7 reports the stock moved an average of 5.4% (up or down) in the day after earnings.
About Mesoblast Limited American Depositary Shares
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-26 | FY 2026 | -0.11 | -0.04 | +91.20% | $120.3M | ✅ Beat | +7.96% | +2.67% | -10.21% |
| 2026-02-26 | H1 2026 | -0.20 | -0.03 | +84.50% | $51.3M | ✅ Beat | -6.32% | -7.33% | -15.13% |
| 2025-02-26 | H1 2025 | — | -4.20 | — | $3.2M | — | -1.15% | -5.73% | -15.39% |
| 2024-08-28 | FY 2024 | — | -8.91 | — | $5.9M | — | +1.57% | +0.63% | +19.31% |
| 2023-08-30 | Q4 2023 | -0.30 | -0.28 | +6.67% | $2.1M | ✅ Beat | +12.59% | +3.85% | -13.99% |
| 2023-05-25 | Q3 2023 | -0.34 | -0.25 | +25.29% | $1.9M | ✅ Beat | +5.22% | +5.22% | +6.67% |
| 2023-02-27 | Q2 2023 | -0.28 | -1.32 | -371.43% | $2.1M | ❌ Miss | +3.13% | +0.63% | -2.50% |
| 2022-11-22 | -0.20 | -0.24 | — | $1.5M | ❌ Miss | — | — | — |
Showing last 8 quarters.